Cash, cash equivalents and short-term investmentswere $83.1M as of March 31, compared to $125.7M as of December 31, 2024. Adverum expects its cash, cash equivalents and short-term investments to fund operations into the second half of 2025.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADVM:
- Adverum Biotechnologies: Promising Gene Therapy Developments and Financial Stability Justify Buy Rating
- Adverum Biotechnologies Reports 2024 Financial Results and Pipeline Progress
- Adverum Biotechnologies reports Q4 EPS ($1.96), consensus ($1.38)
- Adverum Biotechnologies sees cash runway into 2H25
- Adverum Biotechnologies announces anticipated milestones